Nonprofit hospitals must finally prove they earn their tax breaks

What it does

This bill requires nonprofit hospitals that receive tax-exempt status to disclose far more detailed financial information on their annual IRS filings, including how much they spend on community health needs, financial assistance to patients, advertising, and specific service lines like oncology or cardiology. Larger hospitals (over 100 beds) and high-revenue hospitals (over $100 million in net patient revenue) face additional reporting requirements, including disclosure of profits from the federal 340B drug discount program. The bill benefits patients and the public by making it easier to hold nonprofit hospitals accountable for the community benefits they are supposed to provide in exchange for their tax-exempt status.

Why we flagged it

The bill's core function is forcing nonprofit hospitals to publicly justify their tax-exempt status through detailed financial disclosures, making it fundamentally an accountability and transparency measure targeting a sector that receives billions in annual tax benefits.

What the text implies

• The 340B drug discount program reporting requirements could expose how much profit large hospital systems extract from the program — hospitals buy drugs at steep discounts but often bill insurers and patients at full price, and this disclosure could fuel legislative efforts to reform or restrict 340B participation.
• The GAO study mandated in Section 3 explicitly estimates how much tax revenue the federal government foregoes by exempting the 25 largest nonprofit hospital systems — this is a clear legislative signal that future legislation could threaten tax-exempt status for hospitals deemed insufficiently charitable.
• The standardized health service line taxonomy, to be developed by HHS within two years, could become a powerful regulatory tool that reshapes how hospitals organize and report their operations, with compliance costs potentially passed on to patients through higher prices.
• Requiring separate facility-level reporting for large and high-revenue hospital systems may expose cross-subsidization strategies — profitable service lines like orthopedics or cardiology subsidizing unprofitable ones like emergency or psychiatric care — potentially inviting scrutiny or cherry-picking by for-profit competitors.
• The inflation-adjustment mechanism for the $100 million revenue threshold (tied to 2027 baseline) means the definition of 'high revenue' will gradually capture more hospitals over time, expanding the bill's reach without further congressional action.

Who it affects

Ordinary patients and communities gain meaningful transparency into whether nonprofit hospitals are actually delivering community benefits commensurate with their tax exemptions; the bill creates accountability mechanisms that could expose hospitals that pocket tax savings without adequately serving low-income patients or community health needs.

Who stands to gain

• healthcare transparency and compliance technology vendors
• healthcare consulting firms
• health data analytics companies
• patients seeking financial assistance from nonprofit hospitals

Named in the bill

Internal Revenue Service, Centers for Medicare & Medicaid Services, Health Resources and Services Administration, Department of the Treasury, Government Accountability Office, House Committee on Ways and Means, Senate Committee on Finance, 340B drug discount program, Social Security Act section 1815, Public Health Service Act section 340B, IRC section 6033, IRC section 501(r) — and 5 more

Where it stands

1 cosponsor: 1 Republicans.

• Jun 29, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jun 29, 2026 — Referred to House Committee on Ways and Means · Congress.gov: “Referred to the House Committee on Ways and Means”
• Jul 1, 2026 — Markup held in committee · Congress.gov: “Committee Consideration and Mark-up Session Held”
• Jul 1, 2026 — Reported out of committee · Congress.gov: “Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 25 - 15”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

67 lobbying clients named this bill on 68 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $20,520,401 in lobbying spend. A filing names 5 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 99% of bills with at least one filing.

Gregory Murphy, the sponsor, reported $1,068,698 in PAC receipts in the 2026 cycle.

• American Medical Association — $5,643,000 on 2 filings
• American Hospital Association — $4,470,000 on 1 filing
• Biotechnology Innovation Organization — $2,360,000 on 1 filing
• Novartis — $1,410,000 on 1 filing
• Kaiser Foundation Health Plan Inc — $530,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.